Novartis AG





Market Closed - Swiss Exchange 11:31:13 2024-05-23 am EDT 5-day change 1st Jan Change
92.77 CHF -0.42% Intraday chart for Novartis AG +0.16% +9.31%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating MT
NOVARTIS AG : Berenberg remains Neutral ZD
Novartis' Cosentyx Receives Canadian Approval for Hidradenitis Suppurativa Treatment MT
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 DP
Novartis: presents results of tender offer for MorphoSysy CF
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold MT
Novartis to present results at ASCO and EHA CF
Novartis highlights pioneering innovation in CML with data from Scemblix(R) Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA DJ
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales DJ
Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation MT
Novartis Gets FDA Breakthrough Therapy Designation for Scemblix DJ
NOVARTIS AG : UBS maintains a Buy rating ZD
Health Care Flat Amid Mixed Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon MT
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET DJ
Novartis AG to Acquire Mariana Oncology in Deal Valued Up to $1.75 Billion. MT
News Highlights : Top Company News of the Day - Thursday at 9 AM ET DJ
Novartis: acquisition of US-based Mariana Oncology CF
Switzerland's Novartis to Buy US-based Mariana Oncology for $1 Billion Upfront MT
Novartis to Buy Mariana Oncology, Pay $1 Billion Upfront MT
Novartis AG to Acquire Mariana Oncology MT
Novartis AG to Acquire Mariana Oncology MT
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
101.9 USD
Average target price
108.1 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial